Formulary Finder

SELECTED PLANS FOR Breztri :

BREZTRI HCP

Try Later

Change Plans
Plan Type:
State:

Individual costs and benefit design may vary. Please consult with individual plans for specific information. AstraZeneca does not endorse any individual, commercial, Medicare Part D, or Medicaid plan or plans. Source: Fingertip Formulary® Database. Abbreviated month name day, year.Tier 1 = lowest co-pay; Tier 2 = middle-level co-pay (preferred); Tiers 3-7 = higher-level co-pay (non-preferred); For Medicare Part D plans, 'Preferred - Tier 3' refers to the lowest co-pay level for branded products; NC = not covered; NA = data not available; PA = prior authorization; QL = quantity limits; ST = step therapy; OR = other restrictions.

Please select the type of plan you're looking for:

  • Commercial
  • Medicare
  • Medicaid
A-E F-J K-O P-T U-Z

To see formulary coverage for your patients, view access by state. Please select a state and county (optional) to find formulary information for BREZTRI. You can review tier status and manage care coverage for commercial, Medicare, and Medicaid plans.

PRESCRIBE FOR COPD AND ASTHMA AND HAVE CONFIDENCE IN COVERAGE

BREZTRI is covered without prior authorization* for 8 out of 10 Commercial and 9 out of 10 Medicare Part D patients† nationwide.1,2

BREZTRI Aerosphere Zero Pay Savings Program for Eligible Commercially Insured Patients
BREZTRI Aerosphere Zero Pay Savings Program for Eligible Commercially Insured Patients

8 out of 10 commercially insured and eligible patients‡ can get BREZTRI for as low as $0 per month, every month.2§

  • 99.99% of patients using BREZTRI ZERO PAY CARD paid $0.002||

9 out of 10
9 out of 10

  • 81% of Medicare Part D patients pay $50 or less a month out of pocket for their BREZTRI prescription2**

  • 43% of Medicare Part D patients pay $10 or less a month out of pocket for their BREZTRI prescription2**

*“Without Prior Authorization” is defined as additional information is not required to be provided to the health plan in order for BREZTRI to be covered. Step edits may apply.

†“Patients” is defined as covered lives (Commercial, EGWP, Employer, Fed Prog, FEHBP, HIX, Medicare MA, Medicare PDP, Medicare SN, Medi-Medi, Municipal Plan, PACE, PBM, Pvt HIX, Union) at Tiers 1-7 in the nation, as calculated by Fingertip Formulary® as of 4/6/2026.

‡“Patients” is defined as covered lives (Commercial, Employer, Fed Prog, FEHBP, HIX, Municipal Plan, PBM, Pvt HIX, Union) at Tiers 1-7 in the nation, as calculated by Fingertip Formulary® as of 4/6/2026.

§For commercially insured patients. Subject to eligibility and monthly savings limit. Restrictions apply.

||Commercially insured/covered patients with no restrictions (step-edit, prior authorization, or NDC block).

“Preferred Coverage” is defined as Tier 1, Tier 2, or Tier 3 when Tier 3 is the lowest branded tier.

#“Patients” is defined as covered lives (EGWP, Medicare MA, Medicare PDP, Medicare SN, Medi-Medi, PACE) at Tiers 1-3 Preferred in the nation, as calculated by Fingertip Formulary® as of 4/6/2026.

**Excludes rejected claims.

Important Safety Information

IMPORTANT SAFETY INFORMATION

  • BREZTRI is contraindicated:
    • For the primary treatment of status asthmaticus or other acute episodes of asthma or COPD requiring intensive measures
    • In patients who have a hypersensitivity to budesonide, glycopyrrolate, formoterol fumarate or product excipients
  • Long-acting beta2-adrenergic agonist (LABA) monotherapy for asthma is associated with an increased risk of serious asthma-related events. These findings are considered a class effect of LABA monotherapy. When a LABA is used in a fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS use alone. Available data do not suggest an increased risk of death with use of LABA in patients with COPD
  • BREZTRI should not be initiated in patients with acutely deteriorating COPD or asthma, which may be a life-threatening condition
  • BREZTRI is NOT a rescue inhaler. Do NOT use to relieve acute symptoms; treat with an inhaled short-acting beta2-agonist
  • BREZTRI should not be used more often than recommended; at higher doses than recommended; or in combination with LABA-containing medicines, due to risk of overdose. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs
  • Oropharyngeal candidiasis has occurred in patients treated with orally inhaled drug products containing budesonide. Advise patients to rinse their mouths with water without swallowing after inhalation
  • Lower respiratory tract infections, including pneumonia, have been reported following ICS. Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of pneumonia and exacerbations frequently overlap
  • Due to possible immunosuppression, potential worsening of infections could occur. Use with caution. A more serious or fatal course of chickenpox or measles can occur in susceptible patients
  • Particular care is needed for patients transferred from systemic corticosteroids to ICS because deaths due to adrenal insufficiency have occurred in patients during and after transfer. Taper patients slowly from systemic corticosteroids if transferring to BREZTRI
  • Hypercorticism and adrenal suppression may occur with regular or very high dosage in susceptible individuals. If such changes occur, consider appropriate therapy
  • Caution should be exercised when considering the coadministration of BREZTRI with long-term ketoconazole and other known strong CYP3A4 Inhibitors. Adverse effects related to increased systemic exposure to budesonide may occur
  • If paradoxical bronchospasm occurs, discontinue BREZTRI immediately and institute alternative therapy
  • Anaphylaxis and other hypersensitivity reactions (eg, angioedema, urticaria or rash) have been reported. Discontinue and consider alternative therapy
  • Use caution in patients with cardiovascular disorders, especially coronary insufficiency, as formoterol fumarate can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles
  • Decreases in bone mineral density have been observed with long-term administration of ICS. Assess initially and periodically thereafter in patients at high risk for decreased bone mineral content
  • Monitor growth in pediatric patients
  • Glaucoma and cataracts may occur with long-term use of ICS. Worsening of narrow-angle glaucoma may occur, so use with caution. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use BREZTRI long term. Instruct patients to contact a healthcare provider immediately if symptoms occur
  • Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to contact a healthcare provider immediately if symptoms occur
  • Use caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis or unusually responsive to sympathomimetic amines
  • Be alert to hypokalemia or hyperglycemia
  • Most common adverse reactions (incidence ≥ 2%) are:
    • COPD: upper respiratory tract infection, pneumonia, back pain, oral candidiasis, influenza, muscle spasms, urinary tract infection, cough, sinusitis, and diarrhea
    • Asthma: nasopharyngitis, pneumonia, and headache
  • BREZTRI should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors and tricyclic antidepressants, as these may potentiate the effect of formoterol fumarate on the cardiovascular system
  • BREZTRI should be administered with caution to patients being treated with:
    • Strong cytochrome P450 3A4 inhibitors (may cause systemic corticosteroid effects)
    • Adrenergic drugs (may potentiate effects of formoterol fumarate)
    • Xanthine derivatives, steroids, or non-potassium sparing diuretics (may potentiate hypokalemia and/or ECG changes)
    • Beta-blockers (may block bronchodilatory effects of beta-agonists and produce severe bronchospasm)
    • Anticholinergic-containing drugs (may interact additively). Avoid use with BREZTRI
  • Use BREZTRI with caution in patients with hepatic impairment, as budesonide and formoterol fumarate systemic exposure may increase. Patients with severe hepatic disease should be closely monitored

INDICATIONS

BREZTRI AEROSPHERE 160 mcg/9 mcg/4.8 mcg is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.

BREZTRI AEROSPHERE 160 mcg/18 mcg/4.8 mcg is indicated for the maintenance treatment of asthma in adult and pediatric patients 12 years of age and older.

LIMITATIONS OF USE

Not indicated for the relief of acute bronchospasm.

Please see full Prescribing Information, including Patient Information.

You may report side effects related to AstraZeneca products.

Important Safety Information

 +

References

  • 1. Formulary data are provided by Fingertip Formulary® and are current as of 4/6/2026.

  • 2. Data on File, US-100421, AZPLP.

This product information is intended for US Healthcare Professionals only.

BREZTRI AEROSPHERE is a registered trademark of the AstraZeneca group of companies.

©2026 AstraZeneca. All rights reserved. US-102140; US-106667; US-110378; US-112026 Last Updated 6/26